Microphthalmia-associated transcription factor gene amplification in metastatic melanoma is a prognostic marker for patient survival, but not a predictive marker for chemosensitivity and chemotherapy response

Clinical Cancer Research

Volumn 13, Issue 21, 2007, Pages 6344-6350

  Ugurel, Selma ^a   Houben, Roland ^b   Schrama, David ^b   Voigt, Heike ^b   Zapatka, Marc ^c   Schadendorf, Dirk ^a   Bröcker, Eva B ^b   Becker, Jürgen C ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENT; CISPLATIN; DACARBAZINE; DOXORUBICIN; GEMCITABINE; MICROPHTHALMIA ASSOCIATED TRANSCRIPTION FACTOR; PACLITAXEL; TREOSULFAN; TUMOR MARKER; VINDESINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CANCER PATIENT; CANCER SURVIVAL; CELL LINEAGE; CHEMOSENSITIVITY; DISEASE SPECIFIC SURVIVAL; FEMALE; GENE AMPLIFICATION; GENOME ANALYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LUMINESCENCE; MAJOR CLINICAL STUDY; MALE; MELANOCYTE; MELANOMA; ONCOGENE; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; TREATMENT OUTCOME; TREATMENT RESPONSE; VALIDATION PROCESS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MELANOMA; MICROPHTHALMIA-ASSOCIATED TRANSCRIPTION FACTOR; MIDDLE AGED; PROGNOSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 35948985961     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-2682     Document Type: Article

References (20)

1. Widlund HR, Fisher DE. Microphthalamia-associated transcription factor: a critical regulator of pigment cell development and survival. Oncogene 2003;22:3035-41.
2. Carreira S, Goodall J, Aksan I, et al. Mitf cooperates with Rb1 and activates p21Cip1 expression to regulate cell cycle progression. Nature 2005;433:764-9.
3. Loercher AE, Tank EM, Delston RB, Harbour JW. MITF links differentiation with cell cycle arrest in melanocytes by transcriptional activation of INK4A. J Cell Biol 2005;168:35-40.
4. Wu M, Hemesath TJ, Takemoto CM, et al. c-kit triggers dual phosphorylations, which couple activation and degradation of the essential melanocyte factor Mi. Genes Dev 2000;14:301-12.
5. Wellbrock C, Marais R. Elevated expression of MITF counteracts B-RAF-stimulated melanocyte and melanoma cell proliferation. J Cell Biol 2005;170:703-8.
6. McGill GG, Horstmann M, Widlund HR, et al. Bcl2 regulation by the melanocyte master regulator Mitf modulates lineage survival and melanoma cell viability. Cell 2002;109:707-18.
7. Garraway LA, Widlund HR, Rubin MA, et al. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 2005;436:117-22.
8. Koyanagi K, O'Day SJ, Gonzalez R, et al. Microphthalmia transcription factor as a molecular marker for circulating tumor cell detection in blood of melanoma patients. Clin Cancer Res 2006;12:1137-43.
9. Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001;19:3635-48.
10. Ugurel S, Schadendorf D, Pföhler C, et al. In vitro drug sensitivity predicts response and survival after individualized sensitivity-directed chemotherapy in metastatic melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group. Clin Cancer Res 2006;12:5454-63.
11. Andreotti PE, Cree IA, Kurbacher CM, et al. Chemosensitivity testing of human tumors using a microplate adenosine triphosphate luminescence assay: clinical correlation for cisplatin resistance of ovarian carcinoma. Cancer Res 1995;55:5276-82.
12. Therasse P, Arbuck SG, Eisenhauer EA, et al.; European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000;92:205-16.
13. Hothorn T, Lausen B. On the exact distribution of maximally selected rank statistics. Comput Statist Data Anal 2003;43:121-37.
14. Levy C, Khaled M, Fisher DE. MITF: master regulator of melanocyte development and melanoma oncogene. Trends Mol Med 2006;12:406-14.
15. Du J, Widlund HR, Horstmann MA, et al. Critical role of CDK2 for melanoma growth linked to its melanocyte-specific transcriptional regulation by MITF. Cancer Cell 2004;6:565-76.
16. Larribere L, Hilmi C, Khaled M, et al. The cleavage of microphthalmia-associated transcription factor, MITF, by caspases plays an essential role in melanocyte and melanoma cell apoptosis. Genes Dev 2005;19:1980-5.
17. Salti GI, Manougian T, Farolan M, Shilkaitis A, Majumdar D, Das Gupta TK. Micropthalmia transcription factor: a new prognostic marker in intermediate-thickness cutaneous malignant melanoma. Cancer Res 2000;60:5012-6.
18. Selzer E, Wacheck V, Lucas T, et al. The melanocyte-specific isoform of the microphthalmia transcription factor affects the phenotype of human melanoma. Cancer Res 2002;62:2098-103.
19. Miller AJ, Mihm MC, Jr. Melanoma. N Engl J Med 2006;355:51-65.
20. Ugurel S, Houben R, Becker JC. Molecular mechanisms in melanoma. N Engl J Med 2006;355:1395-6.